|
2025 Conference Publication Research Alliance for Urban Goori Health: healthcare records across primary and tertiary healthcare services for Aboriginal and Torres Strait Islander people in South East QueenslandSanjida, Saira, Lane, Steven, Butler, Danielle, Shakeshaft, Anthony, Sullivan, Clair and Ward, James (2025). Research Alliance for Urban Goori Health: healthcare records across primary and tertiary healthcare services for Aboriginal and Torres Strait Islander people in South East Queensland. The 21st Annual International Conference on Urban Health, Wellington, New Zealand, 17-21 November 2025. |
|
2025 Journal Article Durable efficacy of lenzilumab plus azacitidine in newly diagnosed proliferative CMML patients: Interim analysis after four years of study commencementHiwase, Devendra, Ross, David, Yeung, David, Yong, Agnes, Lane, Steven, Brown, Anna, Fong, Chun Yew, Hughes, Timothy, Reynolds, John and Thomas, Daniel (2025). Durable efficacy of lenzilumab plus azacitidine in newly diagnosed proliferative CMML patients: Interim analysis after four years of study commencement. Blood, 146 (Supplement 1), 3855-3855. doi: 10.1182/blood-2025-3855 |
|
2025 Journal Article Unravelling the epigenetic drivers of chip – MDS/CMML – AML progression through novel methylation-sensitive regulatory elementsLiu, Yanjing, Chai, Li, Hiwase, Devendra, Ross, David, Yeung, David, Yong, Agnes, Lane, Steven, Brown, Anna, Fong, Chun Yew, Hughes, Timothy, Reynolds, John, Thomas, Daniel, Tenen, Daniel and Bassal, Mahmoud (2025). Unravelling the epigenetic drivers of chip – MDS/CMML – AML progression through novel methylation-sensitive regulatory elements. Blood, 146 (Supplement 1), 3231-3231. doi: 10.1182/blood-2025-3231 |
|
2025 Conference Publication JAK2V617F myeloproliferative neoplasm-propagating stem cells and pegifna treatment alter the bone marrow nicheJohansson, Alban, Bywater, Megan, Shakhovskoy, Michael, Haldar, Rohit, Cooper, Leanne, Lane, Steven and Straube, Jasmin (2025). JAK2V617F myeloproliferative neoplasm-propagating stem cells and pegifna treatment alter the bone marrow niche. 54th Annual Scientific Meeting of the ISEH - International Society for Experimental Hematology, Kumamoto, Japan, 24-27 September 2025. Amsterdam, Netherlands: Elsevier. doi: 10.1016/j.exphem.2025.105093 |
|
2025 Journal Article Durable Responses to Lenzilumab: Azacitidine Combination Therapy in High Risk Proliferative Chronic Myelomonocytic Leukaemia with Suppression of CBL and RAS Mutant SubclonesThomas, Daniel, Ross, David, Hughes, Timothy, Yeung, David, Kutyna, Monika, Lim, Kelly, Lane, Steven, Yong, Agnes, Reynolds, John and Hiwase, Devendra (2025). Durable Responses to Lenzilumab: Azacitidine Combination Therapy in High Risk Proliferative Chronic Myelomonocytic Leukaemia with Suppression of CBL and RAS Mutant Subclones. EMJ Hematology, 13 (1), 66-67. doi: 10.33590/emjhematol/wvmu7856 |
|
2025 Journal Article Assessing the performance of paediatric early warning scores to predict critical deterioration events in hospitalised children (the DETECT study): a retrospective matched case-control studyBracken, Abbey, Lane, Steven, Siner, Sarah, Jones, Dawn, Lambert, Caroline, Mehta, Fulya, Eyton-Chong, Chin-Kien, Davis, Peter, Fitzsimons, John, Lim, Emma, Clerihew, Linda, Carter, Bernie, Sefton, Gerri and Carrol, Enitan D. (2025). Assessing the performance of paediatric early warning scores to predict critical deterioration events in hospitalised children (the DETECT study): a retrospective matched case-control study. BMC Pediatrics, 25 (1) 520, 1. doi: 10.1186/s12887-025-05754-x |
|
2025 Journal Article Clinical prediction models for febrile neutropenia and its outcomes: a systematic reviewSheehy, Joshua, Gallanagh, Marianne, Sullivan, Clair and Lane, Steven (2025). Clinical prediction models for febrile neutropenia and its outcomes: a systematic review. Supportive Care in Cancer, 33 (7) 537, 537. doi: 10.1007/s00520-025-09562-y |
|
2025 Journal Article Prevention, diagnosis and management of myeloproliferative neoplasms: an introduction to a review seriesYuan, Yin and Lane, Steven W. (2025). Prevention, diagnosis and management of myeloproliferative neoplasms: an introduction to a review series. Haematologica, 110 (4), 825-827. doi: 10.3324/haematol.2024.285414 |
|
2025 Journal Article ALLG APML5: Bioavailability and safety of oral arsenic trioxide assessed during consolidation therapy for APLIland, Harry J., Reynolds, John, Boddy, Alan, Schultz, Hayley B., Khoo, Liane, Fleming, Shaun A., Lane, Steven W., Weber, Nicholas, Gasiorowski, Robin, Armytage, Tasman, Harrup, Rosemary Anne, Watson, Anne-Marie, Tan, Peter, Filshie, Robin, Kwok, Fiona, Stevenson, William S., Yuen, Sam L.S., Ng, Ashley Peng Chee, Rowley, Leesa, Marlton, Paula and Wei, Andrew H. (2025). ALLG APML5: Bioavailability and safety of oral arsenic trioxide assessed during consolidation therapy for APL. Blood Advances, 9 (6), 1476-1484. doi: 10.1182/bloodadvances.2024015397 |
|
2025 Journal Article The PRECISION study protocol: Can cervical stiffness in the second trimester predict preterm birth in high-risk singleton pregnancies? A feasibility, cohort studyMedford, Elizabeth, Lane, Steven, Sharp, Andrew and Care, Angharad (2025). The PRECISION study protocol: Can cervical stiffness in the second trimester predict preterm birth in high-risk singleton pregnancies? A feasibility, cohort study. PLoS One, 20 (2) e0316297, 1-13. doi: 10.1371/journal.pone.0316297 |
|
2024 Conference Publication Single Cell Genotype-Phenotype Analysis Demonstrates That Post-MPN AML Is Driven By Clonal Evolution and Loss of Transcriptional Heterogeneity within Stem Cell CompartmentsStraube, Jasmin, Grabek, Julian, Cooper, Leanne, Haldar, Rohit, McNamara, Caroline, Ross, David M., Perkins, Andrew, Bywater, Megan and Lane, Steven W. (2024). Single Cell Genotype-Phenotype Analysis Demonstrates That Post-MPN AML Is Driven By Clonal Evolution and Loss of Transcriptional Heterogeneity within Stem Cell Compartments. 66th ASH Annual Meeting, San Diego, CA United States, 7-10 December 2024. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood-2024-199841 |
|
2024 Conference Publication Durable Responses Observed in Chronic Myelomonocytic Leukemia Treated with Lenzilumab and AzacitidineHiwase, Devendra, Ross, David M., Yeung, David T., Yong, Agnes S. M., Lane, Steven W., Brown, Anna, Fong, Chun Yew, Hughes, Timothy P., Reynolds, John and Thomas, Daniel (2024). Durable Responses Observed in Chronic Myelomonocytic Leukemia Treated with Lenzilumab and Azacitidine. 66th ASH Annual Meeting, San Diego, CA United States, 7-10 December 2024. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood-2024-202867 |
|
2024 Conference Publication High Dose Ascorbate Reduces Interleukin-1 Beta Secretion in TET2 Mutant Monocytes and Demonstrates Excellent Safety and Tolerability in CMML Patients in Combination with AzacitidineKamel, Maha M., Robinson, Nirmal, Kutyna, Monika, Lim, Kelly, Thompson-Peach, Chloe, Lane, Steven W., Yeung, David T., Yong, Agnes S. M., Ross, David M., Hiwase, Devendra and Thomas, Daniel (2024). High Dose Ascorbate Reduces Interleukin-1 Beta Secretion in TET2 Mutant Monocytes and Demonstrates Excellent Safety and Tolerability in CMML Patients in Combination with Azacitidine. 66th ASH Annual Meeting, San Diego, CA United States, 7-10 December 2024. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood-2024-204177 |
|
2024 Conference Publication Update of the Ascend-CML Study of Frontline Asciminib: High Rate of Optimal Response and Resistance Due to Mutations Is RareYeung, David T., Shanmuganathan, Naranie, Yong, Agnes S. M., Shortt, Jake, Chee, Lynette C.Y., Vialla, Nicholas, Cunningham, Ilona, Ross, David M., D'Souza, Alwyn, Wright, Matthew P.F., Harrup, Rosemary, Forsyth, Cecily, Filshie, Robin, Lane, Steven W., Browett, Peter J., Grove, Carolyn S., Walia, Mannu, Branford, Susan, Reynolds, John, Grigg, Andrew P. and Hughes, Timothy P. (2024). Update of the Ascend-CML Study of Frontline Asciminib: High Rate of Optimal Response and Resistance Due to Mutations Is Rare. 66th ASH Annual Meeting, San Diego, CA United States, 7-10 December 2024. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood-2024-201218 |
|
2024 Conference Publication Overcoming Ven/Aza Resistance through Imetelstat-Mediated Lipophagy in Acute Myeloid LeukemiaBruedigam, Claudia, Dulatre, Eunice Anne, Lee, Carol, Porter, Amy H., Lim, Elisa L.S.P., Shi, Alexander Z., Hodson, Mark P., Heidel, Florian H. and Lane, Steven W. (2024). Overcoming Ven/Aza Resistance through Imetelstat-Mediated Lipophagy in Acute Myeloid Leukemia. 66th ASH Annual Meeting, San Diego, CA United States, 7-10 December 2024. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood-2024-206473 |
|
2024 Conference Publication Dnmt3a Mutation Promotes Expansion of a Quiescent Myeloid Progenitor Population in Npm1c-Flt3ITD Acute Myeloid LeukemiaTavakoli, Paniz, Bywater, Megan, Straube, Jasmin, Ling, Victoria, Cooper, Emily, Haldar, Rohit, Janardhanan, Yashaswini, Cooper, Leanne, Bruedigam, Claudia, Grove, Carolyn S. and Lane, Steven W. (2024). Dnmt3a Mutation Promotes Expansion of a Quiescent Myeloid Progenitor Population in Npm1c-Flt3ITD Acute Myeloid Leukemia. 66th ASH Annual Meeting, San Diego, CA United States, 7-10 December 2024. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood-2024-201250 |
|
2024 Conference Publication CBL Variants in Chronic Myelomonocytic Leukemia Exhibit a Complex Sub-Clone Architecture with a High Frequency of RING Domain Mutations Sufficient to Induce GM-CSF HypersensitivityLim, Kelly, Kutyna, Monika, Kan, Winnie, Lopez, Angel F., Brown, Anna, Yong, Agnes S. M., Lane, Steven W., Fong, Chun Yew, Hughes, Timothy P., Yeung, David T., Ross, David M., Hiwase, Devendra and Thomas, Daniel (2024). CBL Variants in Chronic Myelomonocytic Leukemia Exhibit a Complex Sub-Clone Architecture with a High Frequency of RING Domain Mutations Sufficient to Induce GM-CSF Hypersensitivity. 66th ASH Annual Meeting, San Diego, CA United States, 7-10 December 2024. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood-2024-202682 |
|
2024 Journal Article CBL mutations in chronic myelomonocytic leukemia often occur in the RING domain with multiple subclones per patient: Implications for targetingLim, Kelly, Kan, Winnie L., Nair, Pramod C., Kutyna, Monika, Lopez, Angel F., Hercus, Timothy, Ross, David M., Lane, Steven, Fong, Chun Yew, Brown, Anna, Yong, Agnes, Yeung, David, Hughes, Timothy, Hiwase, Devendra and Thomas, Daniel (2024). CBL mutations in chronic myelomonocytic leukemia often occur in the RING domain with multiple subclones per patient: Implications for targeting. PLoS One, 19 (9 September) e0310641, 1-19. doi: 10.1371/journal.pone.0310641 |
|
2024 Journal Article Identifying disease-modifying potential in myelofibrosis clinical trialsRoss, David M, Lane, Steven W and Harrison, Claire N. (2024). Identifying disease-modifying potential in myelofibrosis clinical trials. Blood Journal, 144 (16), 1679-1688. doi: 10.1182/blood.2024024220 |
|
2024 Journal Article Asciminib monotherapy as frontline treatment of chronic-phase chronic myeloid leukemia: results from the ASCEND StudyYeung, David T., Shanmuganathan, Naranie, Reynolds, John, Branford, Susan, Walia, Mannu, Yong, Agnes S.M., Shortt, Jake, Chee, Lynette, Viiala, Nicholas, Cunningham, Ilona, Ross, David M., D'Souza, Alwyn Bernard, Wright, Matthew, Harrup, Rosemary Anne, Forsyth, Cecily Jane, Filshie, Robin, Lane, Steven W., Browett, Peter J., Grove, Carolyn S., Grigg, Andrew A. and Hughes, Timothy P. (2024). Asciminib monotherapy as frontline treatment of chronic-phase chronic myeloid leukemia: results from the ASCEND Study. Blood Journal, 144 (19), 1993-2001. doi: 10.1182/blood.2024024657 |
